Link

Description

Comments

Patent # 4,296,104

The use of urea and/or ethanol with pharmaceutical compositions containing DMSO is disclosed. The result is a reduction in the undesirable side-effects normally associated with the application of DMSO compositions, enhancement of the desired physiological effects produced by DMSO compositions, and other benefits. Specific compositions contain DMSO with urea and/or alcohol and may also contain NaCl, KCl and/or acetamide.

Patent #4,296,130

Preparations containing methylsulfonylmethane (MSM) for administration to the skin, nails, other tissue and/or body fluids of a human or other animal subject are disclosed. Such compositions soften skin, strengthen nails and provide other benefits when applied topically. And, MSM compositions may also be administered orally, by injection and by inhalation.

Preparations containing methylsulfonylmethane (MSM) for administration to the skin, nails, other tissue and/or body fluids of a human or other animal subject are disclosed. Such compositions soften skin, strengthen nails and provide other benefits when applied topically. And, MSM compositions may also be administered orally, by injection and by inhalation.

Patent # 4,514,421

Methylsulfonylmethane (CH(3) SO(2) CH(3)) administered orally is effective in ameliorating the symptoms of gastrointestinal upset, e.g., produced by the ingestion of aspirin and other pharmaceuticals, and of allergic reactions. Oral compositions containing a mixture of such a pharmaceutical and methylsulfonylmethane are useful in avoiding the gastrointestinal upset which otherwise occurs when ingesting the former.

Methylsulfonylmethane (CH(3) SO(2) CH(3)) administered orally is effective in ameliorating the symptoms of gastrointestinal upset, e.g., produced by the ingestion of aspirin and other pharmaceuticals, and of allergic reactions. Oral compositions containing a mixture of such a pharmaceutical and methylsulfonylmethane are useful in avoiding the gastrointestinal upset which otherwise occurs when ingesting the former.

Methylsulfonylmethane (MSM) is useful as a tableting and granulating aid for pharmaceutically active agents, especially those which are unstable in the presence of moisture, mixtures therewith being or formable into free-flowing powders or granules which are readily compressible into tablets of improved properties. A preferred method of forming such powders or granules involves mixing the pharmaceutically active agent under substantially anhydrous conditions with molten MSM or with particulate solid MSM at its softening point, cooling the resultant mixture and, when the MSM was molten, forming the solidified melt into granules or a free flowing powder and thereafter, if desired, compressing the powder or granules into tablets.

Methylsulfonylmethane is effective in maintaining good health and in improving poor health of animals, including human beings and is an assimilable source of dietetic sulfur.

Patent #4,863,748

Methylsulfonylmethane is effective in maintaining good health and in improving poor health of animals, including human beings and is an assimilable source of dietetic sulfur.

Methylsulfonylmethane is effective in treating parasitic infections in animals, including human beings.

Patent # 4,973,605

Methylsulfonylmethane is effective to relieve pain and nocturnal cramps and to reduce stress-induced deaths in animals.

Patent # 5,071,878

The diet of an animal is enhanced by providing to the animal for ingestion a beneficial amount of methylsulfonylmethane which is in addition to any amount present as a naturally occurring constituent in the foodstuff ingested by the animal. The methylsulfonylmethane is an assimilable source of dietetic sulfur and is effective in maintaining good health and improving poor health of animals, including human beings.

Patent # 5,569,679

A method of pharmaceutically managing snoring is provided by the instillation intranasally of a solution containing 1-20% methylsulfonylmethane by weight dissolved in water so as to saturate the nasal mucous membranes. Preferably, the solution has between 10%-16% by weight methysulfonylmethane. The solution may be buffered, and/or a mild analgesic may be included. The method prefers that instillation occur as close to the sleep event as possible, and it should be at least within one hour before a person retires for sleep. The solution may be introduced by spray or drop-wise, and a product packaging the solution in a suitable container is described.

Separate Search Page
or search below